Researchers from North Carolina State University found that urine ammonia levels may identify dogs at higher risk for rapid chronic kidney disease progression [1].
This discovery offers veterinarians a non-invasive tool to determine which animals require more aggressive therapies to slow the decline of organ function. By identifying high-risk patients early, clinicians can potentially extend the lives of dogs facing this debilitating condition [1].
The study focused on the urine ammonia-to-creatinine ratio, known as UACR [1]. The data indicates that dogs with lower UACR experience faster progression of chronic kidney disease and higher fatality rates [1, 2]. This suggests that the ratio serves as a reliable marker for disease severity [2].
Chronic kidney disease is a progressive condition that affects the ability of the kidneys to filter waste from the blood. Because the disease often advances silently, finding a biomarker that can predict the speed of decline is critical for effective management [1].
The researchers developed this method to help veterinarians target specific therapies toward the dogs most likely to benefit from them [1, 2]. This targeted approach allows for more personalized care based on the biological markers of the individual animal [2].
The study was conducted at the university's facilities in the U.S. and was published in May 2026 [1, 2].
“Dogs with lower urine ammonia‑to‑creatinine ratios experience faster progression of chronic kidney disease.”
The identification of UACR as a prognostic marker shifts the management of canine kidney disease from a reactive approach to a predictive one. By quantifying the risk of rapid progression through a simple urine test, veterinarians can justify more intensive interventions for high-risk dogs while avoiding over-treatment in those with a slower disease trajectory.
